Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Duke University
mi
from
Durham, NC
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
University Hospitals
mi
from
Cleveland, OH
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
University Hospitals
mi
from
Cleveland, OH
Click here to add this to my saved trials
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Lehigh Valley Health Network
mi
from
Allentown, PA
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Lehigh Valley Health Network
mi
from
Allentown, PA
Click here to add this to my saved trials
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
UPMC Cancer Center
mi
from
Pittsburgh, PA
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
UPMC Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Univ Of Tx. Md Anderson
mi
from
Houston, TX
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Univ Of Tx. Md Anderson
mi
from
Houston, TX
Click here to add this to my saved trials
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Cancer Centers of South Texas
mi
from
San Antonio, TX
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Cancer Centers of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Coiba
mi
from
Berazategui,
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Coiba
mi
from
Berazategui,
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Hot Springs, AZ
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Hot Springs, AZ
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Washington,
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Orlando, FL
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Detroit, MI
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Pascagoula, MS
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Pascagoula, MS
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Kansas City, MO
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Omaha, NE
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Lebanon, NH
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Goldsboro, NC
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Cleveland, OH
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Gettysburg, PA
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Gettysburg, PA
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Hershey, PA
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Hershey, PA
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Pawtucket, RI
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Pawtucket, RI
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Spartanburg, SC
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/18/2018
Clinical Research Facility
mi
from
Round Rock, TX
Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/18/2018
Clinical Research Facility
mi
from
Round Rock, TX
Click here to add this to my saved trials
5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer
Phase II Trial of Chemoimmunotherapy With 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer
Status: Enrolling
Updated:  1/22/2018
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer
Phase II Trial of Chemoimmunotherapy With 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer
Status: Enrolling
Updated: 1/22/2018
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Click here to add this to my saved trials
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
Promoting Informed Decisions About Lung Cancer Screening: Decision Aid Update and Measures Development
Status: Enrolling
Updated:  1/22/2018
University of Texas Medical Branch at Galveston
mi
from
Galveston, TX
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
Promoting Informed Decisions About Lung Cancer Screening: Decision Aid Update and Measures Development
Status: Enrolling
Updated: 1/22/2018
University of Texas Medical Branch at Galveston
mi
from
Galveston, TX
Click here to add this to my saved trials
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
Promoting Informed Decisions About Lung Cancer Screening: Decision Aid Update and Measures Development
Status: Enrolling
Updated:  1/22/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
Promoting Informed Decisions About Lung Cancer Screening: Decision Aid Update and Measures Development
Status: Enrolling
Updated: 1/22/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer
A Phase III, Randomized, Study of Weekly Taxoprexin Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/22/2018
US Oncology
mi
from
Dallas, TX
Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer
A Phase III, Randomized, Study of Weekly Taxoprexin Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/22/2018
US Oncology
mi
from
Dallas, TX
Click here to add this to my saved trials
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/24/2018
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/24/2018
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/24/2018
Rush Cancer Institute at Rush University Medical Center
mi
from
Chicago, IL
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/24/2018
Rush Cancer Institute at Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/24/2018
Evanston Northwestern Healthcare - Evanston Hospital
mi
from
Evanston, IL
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/24/2018
Evanston Northwestern Healthcare - Evanston Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/24/2018
Ingalls Cancer Care Center at Ingalls Memorial Hospital
mi
from
Harvey, IL
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/24/2018
Ingalls Cancer Care Center at Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/24/2018
Advocate Lutheran General Cancer Care Center
mi
from
Park Ridge, IL
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/24/2018
Advocate Lutheran General Cancer Care Center
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Berkeley, CA
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Berkeley, CA
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Santa Rosa, CA
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Boynton Beach, FL
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Fort Myers, FL
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Jacksonville, FL
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Wichita, KA
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Lexington, KY
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Louisville, KY
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Metairie, LA
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Baltimore, MD
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Columbia, MO
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Columbia, MO
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Latham, NY
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Latham, NY
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Hickory, NC
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Canton, OH
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials